Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin.
For the treatment of rabbit endocarditis, dalbavancin given once daily (10 mg/kg of body weight for 4 days) or as a single 40-mg/kg dose was active against Staphylococcus aureus with or without reduced susceptibility to glycopeptides, as expected from its good in vitro activity, even in broth supplemented with 90% serum and given its prolonged elimination half-life.
Lefort
Agnès
A
Faculté de Médecine Xavier Bichat and University Paris VII, 75018 Paris, France. aglefort@yahoo.com
Pavie
Juliette
J
Garry
Louis
L
Chau
Françoise
F
Fantin
Bruno
B
D000818:Animals; D019540:Area Under Curve; D015169:Colony Count, Microbial; D024881:Drug Resistance, Bacterial; D004697:Endocarditis, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006020:Glycopeptides / Q000627:therapeutic use*; D006207:Half-Life; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology; D017334:Teicoplanin / Q000494:pharmacology* / Q000031:analogs & derivatives; D020713:Vancomycin Resistance
D006020:Glycopeptides; D017334:Teicoplanin; C469289:dalbavancin